

Palliative pylorus-preserving pancreatic head resection and postoperative chemotherapy versus primary chemotherapy alone for patients with advanced carcinoma of the pancreatic head

Submission date 24/05/2007	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 02/07/2007	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 21/09/2007	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Jan Langrehr

Contact details
Department of Surgery
Evangelisches Waldkrankenhaus Spandau
Stadtrandstrasse 555
Berlin
Germany
13589
+49 (0)30 3702 1101
j.langrehr@waldkrankenhaus.com

Additional identifiers

Protocol serial number
2002

Study information

Scientific Title

Acronym

Palliative Pylorus-Preserving Pancreatoduodenectomy (Palliative PPPD)

Study objectives

Survival and quality of life after palliative pylorus-preserving pancreatoduodenectomy and postoperative chemotherapy with Gemzar® is increased when compared to Gemzar® chemotherapy alone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from local Institutional Review Board (IRB) (Ethics Board of the Charité, Medical Faculty, Humboldt University, now known as the Ethics Committee State Berlin) on the 30th August 2002.

Primary study design

Interventional

Study design

Open prospective randomised study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pancreatic head carcinoma

Interventions

Group 1: standard pylorus-preserving pancreatic head resection with regional lymphadenectomy (this is an internationally well accepted surgical procedure) and after completion of wound healing (up to four weeks postoperative) standard chemotherapy with gemcitabine is started (see below). The chemotherapy is the same as in group 2.

Group 2: standard gemcitabine chemotherapy alone: 1000 mg/m² body surface once per week for four weeks with a one-week break, i.e., three weeks treatment and one week free. This is an internationally accepted standard for gemcitabine in advanced pancreatic carcinoma treatment.

Drugs will be administered on an out patient basis intravenously (i.v.) through a port system. Follow up period is one year.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Gemcitabine (Gemzar®)

Primary outcome(s)

Survival, measured after 3, 6 and 12 months

Key secondary outcome(s)

1. Quality of life, measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) and the EORTC Quality of Life Questionnaire for Pancreatic cancer (QLQ PAN26). This will be measured after 3, 6 and 12 months
2. Surgical complications, measured after 3, 6 and 12 months
3. Toxicity of chemotherapy, measured after 3, 6 and 12 months

Completion date

31/12/2009

Eligibility

Key inclusion criteria

Medical centres experienced in surgical and medical care of patients with pancreatic head carcinoma.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

No exclusion criteria.

Date of first enrolment

15/09/2003

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

Germany

Study participating centre
Department of Surgery
Berlin
Germany
13589

Sponsor information

Organisation
Humboldt University Berlin (Germany)

ROR
<https://ror.org/01hcx6992>

Funder(s)

Funder type
University/education

Funder Name
Humboldt University Berlin (Germany) - Department of Surgery at Charité Campus Virchow Clinic

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration